Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.

In the group receiving 100 mg vildagliptin daily and continuing metformin treatment, more than three-quarters of patients experienced a meaningful (41.3%) or marked (37.1%) improvement in glycemic ...